Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Recent developments in neoadjuvant therapy

Prof Gunter Von Minckwitz – German Breast Group, Neu-Isenburg, Germany

Recent developments in neoadjuvant therapy ( Prof Gunter Von Minckwitz – German Breast Group, Neu-Isenburg, Germany )

Highlights and goals of IMPAKT 2012

Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium

Highlights and goals of IMPAKT 2012 ( Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium )

PI3K and the heterogeneity of small tumour breast cancer

Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium

PI3K and the heterogeneity of small tumour breast cancer ( Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium )

Molecularly characterising triple negative breast cancer

Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium

Molecularly characterising triple negative breast cancer ( Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium )

Endocrine therapy and endocrine resistant breast cancer

Prof Mitch Dowsett – The Institute for Cancer Research, London, UK

Endocrine therapy and endocrine resistant breast cancer ( Prof Mitch Dowsett – The Institute for Cancer Research, London, UK )

Neoadjuvant therapy and PCR through chemotherapy prior to surgery

Dr Michail Ignatiadis – Jules Bordet Institute, Brussels, Belgium

Neoadjuvant therapy and PCR through chemotherapy prior to surgery ( Dr Michail Ignatiadis – Jules Bordet Institute, Brussels, Belgium )

Minimising recurrence by using most effective treatment

Prof Fabrice Andre – Institut Gustave Roussy, Paris, France

Minimising recurrence by using most effective treatment ( Prof Fabrice Andre – Institut Gustave Roussy, Paris, France )

Overcoming drug resistance and targeting critical pathways

Dr Larry Norton – Memorial Sloan-Kettering Cancer Center, New York, USA

Overcoming drug resistance and targeting critical pathways ( Dr Larry Norton – Memorial Sloan-Kettering Cancer Center, New York, USA )

Heterogeneity of tumours and the challenges of biomarker development

Prof Giuseppe Curigliano – European Institute of Oncology, Milan, Italy

Heterogeneity of tumours and the challenges of biomarker development ( Prof Giuseppe Curigliano – European Institute of Oncology, Milan, Italy )

Targeting the PI3K/mTOR pathway

Dr Lewis Cantley – Dana-Farber Cancer Institute, Boston, USA

Targeting the PI3K/mTOR pathway ( Dr Lewis Cantley – Dana-Farber Cancer Institute, Boston, USA )

Use of metformin against breast cancer

Prof Alastair Thompson – University of Dundee, UK

Use of metformin against breast cancer ( Prof Alastair Thompson – University of Dundee, UK )

Criteria required before implementation of whole genome arrays in clinical...

Prof Daniel Hays - University of Michigan, Ann Arbor, USA

Criteria required before implementation of whole genome arrays in clinical practice ( Prof Daniel Hays - University of Michigan, Ann Arbor, USA )

More from ecancer